High frequency of expression of MAGE genes in human hepatocellular carcinoma

Chen, Chien‐Hung; Huang, Guan‐Tarn; Lee, Hsuan-Shu; Yang, Pei–Ming; Yan, Ming‐De; Chen, Ding‐Shinn; Sheu, Jin‐Chuan

doi:10.1111/j.1478-3231.1999.tb00019.x

Cited by 31 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite improvement in sonographic examinations and therapy for HCC, the outcome generally remains unsatisfactory. Recently, the expression of CT antigen-encoding genes in HCC tissues has been reported by several laboratories (7)(8)(9)(10). Our own data have revealed that mRNA for at least 20 CT antigens can be detected in HCC tissues.…”

Section: Introductionmentioning

confidence: 63%

The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients

Shang

Chen²,

Zhang

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 63%

The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients

Shang

Chen²,

Zhang

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

“…In the case of HCC, the positive rate was 46 -80% of MAGE-1 transcript and 42 -68% of MAGE-3 transcript in HCC tissue samples (Cai et al, 1999(Cai et al, , 2000Chen et al, 1999;Tahara et al, 1999;Yamashita et al, 1996). A proportion of 74 -86% of the HCC tissue samples was positive for at least one MAGE gene transcript, while no expression of MAGE transcripts detected in the surrounding non-cancerous tissues, nor in the livers of cirrhosis, HBV/HCV infection or normal ones (Cai et al, 1999(Cai et al, , 2000Chen et al, 1999;Tahara et al, 1999;Yamashita et al, 1996). We have reported previously that MAGE-1 and MAGE-3 transcripts were expressed in 71 and 78% of resected HCC tissue samples, respectively (Cai et al, 1999;.…”

Section: Discussionmentioning

confidence: 99%

“…Because of this distribution characteristic, the MAGE proteins are termed as cancer-testes (CT) antigens (De Plaen et al, 1994). Both others and our group have reported that MAGE-1 and MAGE-3 transcripts were highly expressed in HCC tissues, but not in non-HCC liver tissues, nor in non-HCC liver diseases such as HBV/HCV infection and cirrhosis (Cai et al, 1999(Cai et al, , 2000Chen et al, 1999;Tahara et al, 1999;Yamashita et al, 1996). Therefore, we investigated if the MAGE gene transcripts could be used as tumour marker to specifically detect metastasis of HCC cells in peripheral blood.…”

mentioning

confidence: 99%

Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells

Mou

Peng

et al. 2002

Br J Cancer

View full text Add to dashboard Cite

The members of MAGE gene family are highly expressed in human hepatocellular carcinoma (HCC). In the present study, we tested the tumour-specific MAGE-1 and MAGE-3 transcripts in the peripheral blood of HCC patients by nested RT -PCR to detect the circulating tumour cells and evaluate their potential clinical implication. Of 30 HCC patients, the positive rate of MAGE-1 and MAGE-3 transcripts was 43.3% (13 out of 30) and 33.3% (10 out of 30) in PBMC samples, whilst the positive rate was 70% (21 out of 30) and 53.3% (16 out of 30) in the resected HCC tissue samples, respectively. The positivity for at least one MAGE gene transcript was 63.3% (19 out of 30) in PBMC samples of HCC patients and 83.3% (25 out of 30) in the resected HCC tissue samples. MAGE-1 and/or MAGE-3 mRNA were not detected in the PBMC of those patients from whom the resected HCC tissues were MAGE-1 or MAGE-3 mRNA negative, nor in the 25 PBMC samples from healthy donors. The detection of MAGE transcripts in PBMC was correlated with the advanced stages and tumour size of the HCC, being 82.4% (14 out of 17) in tumour stages III and IVa, 56.6% (five out of nine) in stage II, and null (nought out of four) in stage I. The serum a-FP in 33.3% (10 out of 30) of HCC patients was normal or slightly elevated (540 ng ml 71). However, six of these 10 patients (a-FP 540 ng ml 71 ) were MAGE-1 and /or MAGE-3 mRNA positive in their PBMC. The follow-up survey of MAGE mRNA in PBMC was performed in 12 patients. Seven patients with persistent MAGE-1 and/or MAGE-3 mRNA positive or from negative turned to positive died because of metastasis and/or recurrence. In striking contrast, all four patients with MAGE-1 and/or MAGE-3 mRNA from positive turned to negative and one patient with persistent MAGE-3 transcript negative are alive after last test. Collectively, detection of MAGE transcripts with follow-up survey in PBMC is a feasible and reliable assay for the early prediction of the relapse and prognosis of the HCC patients.

show abstract

“…have been reported [96][97][98][99][100][101][102][103][104][105][106][107][108] . Data from both the literature [109][110][111][112] and from the author's institution [113] demonstrated that human malenoma antigen (MAGE) gene expression is frequent in HCC, suggesting that HCC patients may be good candidates for specific immunotherapy (tumor vaccine) using MAGE encoded antigen. Dendrite cells are good candidates for this particular purpose [114] .…”

Section: Biotherapy Will Play a Role In The Treatment Of Hcc In The Fmentioning

confidence: 99%

Hepatocellular Carcinoma-Cause, Treatment and Metastasis

Tang

2001

WJG

338

220

View full text Add to dashboard Cite

Abbreviation HCC-hepatocellular carcinoma, HBVhepatitis B virus, HCV-hepatitis C virus, HGV-hepatitis G virus, TTV-transfusion transmitted virus, AFB1-aflatoxin B1, IFN-interferon, OLT-orthotopic liver transplantation, PH-partial hepatectomy, RCT-randomized controlled trial, TACE-transcatheter arterial chemoembolization, PEIpercutaneous ethanol injection, PMCT-percutaneous microwave coagulation therapy, RF-radiofrequency, AFPalpha fetoprotein, VEGF-vascular endothelial growth factor. AbstractIn the recent decades, the incidence of hepatocellular carcinoma (HCC) has been found to be increasing in males in some countries. In China, HCC ranked second of cancer mortality since 1990s. Hepatitis B and C viruses (HBV and HCV) and dietary aflatoxin intake remain the major causative factors of HCC. Surgery plays a major role in the treatment of HCC, particularly for small HCC. Downstaging unresectable huge HCC to smaller HCC and followed by resection will probably be a new approach for further study. Liver transplantation is indicated for small HCC, however, some issues remain to be solved. Different modes of "regional cancer therapy for HCC" have been tried. Systemic chemotherapy has been disappointing in the past but the future can be promising. Biotherapy, such as cytokines, differentiation inducers, anti-angiogenic agents, gene therapy and tumor vaccine will probably play a role, particularly in the prevention of tumor recurrence. HCC invasiveness is currently the major target of study. Tremendous works have been done at the molecular level, which will provide clues for biomarker of HCC progression as well as targets for intervention.

show abstract

High frequency of expression of MAGE genes in human hepatocellular carcinoma

Abstract: The MAGE genes are expressed in a high percentage of hepatocellular carcinomas; the MAGE gene products are potential targets for tumor-specific immunotherapy.

Cited by 31 publications

References 29 publications

The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients

The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients

Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells

Hepatocellular Carcinoma-Cause, Treatment and Metastasis

Contact Info

Product

Resources

About